The Biologics Global Market Report 2020-30 by The Business Research Company describes and explains the global biologics market and covers 2015 to 2020, termed the historic period, and 2020 to 2025, termed the forecast period, along with further forecasts for the period 2025-2030. The report evaluates the market across each region and for the major economies within each region.
The Biologics Global Market Opportunities And Strategies Report covers biologics market drivers, biologics market trends, biologics market segments, biologics market growth rate, biologics market major players, and biologics market size.
View Complete Report: https://www.thebusinessresearchcompany.com/report/biologics-market
The biologics market report focuses particularly on identifying the trends, opportunities, and strategies that can lead to success. O&S reports are available off the shelf and can be delivered to clients on the day of purchase.
Biologics Global Market Opportunities And Strategies Report is the most comprehensive report available on this market and will help gain a truly global perspective as it covers 60 geographies. The chapter on the impact of COVID-19 gives valuable insights on supply chain disruptions, logistical challenges, and other economic implications of the virus on the market. The chapter also covers markets which have been positively affected by the pandemic.
Request For The Sample Now: https://www.thebusinessresearchcompany.com/sample.aspx?id=792&type=smp
Trends in the market include:
Robust Research & Development- The biologics market is witnessing robust research and development activities. These research and development activities have led to increasing success rates in clinical trials for biologics. Research and development is being carried out by market leaders in the biologics market as they continuously strive to make breakthroughs in the market in the form of new and effective biologics. For instance, Biocon Limited is developing tregopil, an oral prandial insulin to treat patients with type 2 diabetes, which is in phase II/III clinical trials. Currently, insulin tregopil is in Phase II/III clinical study for Type 2 diabetes patients. In 2019, Jerusalem based Oramed Pharmaceuticals developed an oral insulin drug, which is in phase-2 trials, named ORMD-0801 to treat type-2 diabetes. In September 2019, Novo Nordisk, a Danish multinational pharmaceutical company, received approval from the US Food and Drug Administration to introduce its Rybelsus oral drug for diabetes. Rybelsus drug is an oral form of semaglutide and used to treat patients with type 2 diabetes.
Demand For Biologics In The Treatment Of Complex Diseases- Biologics are being widely used to provide effective treatment for many complex diseases such as rheumatoid arthritis, psoriasis, and Crohn’s disease that have limited treatment options. There has been a significant improvement in the treatment of rheumatoid arthritis patients who do not respond to traditional disease-modifying anti-rheumatic drugs. The key biologics used for the treatment of rheumatoid arthritis include Abatacept (Orencia), Adalimumab (Humira), Anakinra (Kineret), Infliximab (Remicade), and Rituximab (Rituxan). Key biologics used to treat psoriasis include Adalimumab (Humira), Etanercept (Enbrel), Infliximab (Remicade), Secukinumab ( Cosentyx). Cimzia (certolizumab pegol), Humira (adalimumab), and Remicade (infliximab), Tysabri (natalizumab) are biologics that are used to treat Crohn’s disease.
The market is segmented:
By Type-
1. Monoclonal Antibodies
2. Therapeutic Proteins
By Route Of Administration –
1. Oral
2. Others (IV or IP)
By Drug Classification -
1. Branded Drugs
2. Generic Drugs
By Mode Of Purchase -
1. Prescription Drugs
2. OTC Drugs
By Distribution Channel -
1. Hospital Pharmacies
2. Retail Pharmacies
3. Online Pharmacies
About The Business Research Company:
The Business Research Company is a market intelligence firm that excels in company, market, and consumer research. Located globally it has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services, chemicals, and technology. It has offices in the UK, the US and India and a network of trained researchers in 20+ countries globally.
Contact Information:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow us on LinkedIn: https://in.linkedin.com/company/the-business-research-company
Follow us on Twitter: https://twitter.com/tbrc_info
Check out our Blog: http://blog.tbrc.info/
